82_FR_6587 82 FR 6575 - Medical Product Communications That Are Consistent With the Food and Drug Administration-Required Labeling-Questions and Answers; Draft Guidance for Industry; Availability

82 FR 6575 - Medical Product Communications That Are Consistent With the Food and Drug Administration-Required Labeling-Questions and Answers; Draft Guidance for Industry; Availability

DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration

Federal Register Volume 82, Issue 12 (January 19, 2017)

Page Range6575-6578
FR Document2017-01012

The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled ``Medical Product Communications That Are Consistent With the FDA-Required Labeling--Questions and Answers.'' This draft guidance provides information for manufacturers, packers, and distributors and their representatives (collectively ``firms'') of drugs and medical devices for humans, including those that are licensed as biological products, and animal drugs (collectively ``medical products''), about how FDA evaluates their medical product communications, including their promotional materials, that present information that is not contained in the FDA-required labeling for the product but that may be consistent with the FDA-required labeling for the product. The Agency is issuing this draft guidance to explain FDA's current thinking on commonly asked questions regarding such communications in order to provide clarity for firms.

Federal Register, Volume 82 Issue 12 (Thursday, January 19, 2017)
[Federal Register Volume 82, Number 12 (Thursday, January 19, 2017)]
[Notices]
[Pages 6575-6578]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-01012]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2016-D-2285]


Medical Product Communications That Are Consistent With the Food 
and Drug Administration-Required Labeling--Questions and Answers; Draft 
Guidance for Industry; Availability

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice of availability.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
the availability of a draft guidance for industry entitled ``Medical 
Product Communications That Are Consistent With the FDA-Required 
Labeling--Questions and Answers.'' This draft guidance provides 
information for manufacturers, packers, and distributors and their 
representatives (collectively ``firms'') of drugs and medical devices 
for humans, including those that are licensed as biological products, 
and animal drugs (collectively ``medical products''), about how FDA 
evaluates their medical product communications, including their 
promotional materials, that present information that is not contained 
in the FDA-required labeling for the product but that may be consistent 
with the FDA-required labeling for the product. The Agency is issuing 
this draft guidance to explain FDA's current thinking on commonly asked 
questions regarding such communications in order to provide clarity for 
firms.

DATES: Although you can comment on any guidance at any time (see 21 CFR 
10.115(g)(5)), to ensure that the Agency considers your comment on this 
draft guidance before it begins work on the final version of the 
guidance, submit either electronic or written comments on the draft 
guidance by April 19, 2017.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a

[[Page 6576]]

third party may not wish to be posted, such as medical information, 
your or anyone else's Social Security number, or confidential business 
information, such as a manufacturing process. Please note that if you 
include your name, contact information, or other information that 
identifies you in the body of your comments, that information will be 
posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the manner 
detailed (see ``Written/Paper Submissions'' and ``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of 
Dockets Management, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2016-D-2285 for ``Medical Product Communications That Are 
Consistent With the FDA-Required Labeling--Questions and Answers; Draft 
Guidance for Industry; Availability.'' Received comments will be placed 
in the docket and, except for those submitted as ``Confidential 
Submissions,'' publicly viewable at https://www.regulations.gov or at 
the Division of Dockets Management between 9 a.m. and 4 p.m., Monday 
through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Division of Dockets Management. If you do not 
wish your name and contact information to be made publicly available, 
you can provide this information on the cover sheet and not in the body 
of your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: http://www.fda.gov/regulatoryinformation/dockets/default.htm.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Division of Dockets Management, 5630 Fishers 
Lane, Rm. 1061, Rockville, MD 20852.
    Submit written requests for single copies of the draft guidance to 
the Division of Drug Information, Center for Drug Evaluation and 
Research, Food and Drug Administration, 10001 New Hampshire Ave., 
Hillandale Building, 4th Floor, Silver Spring, MD 20993-0002; Office of 
Communication, Outreach and Development, Center for Biologics 
Evaluation and Research, Food and Drug Administration, 10903 New 
Hampshire Ave., Bldg. 71, Rm. 3128, Silver Spring, MD 20993-0002; 
Division of Small Manufacturers, International and Consumer Assistance, 
Office of Communication, Education and Radiation Programs, Center for 
Devices and Radiological Health, Food and Drug Administration, 10903 
New Hampshire Ave., Bldg. 66, Rm. 4613, Silver Spring, MD 20993-0002; 
or to Communications Staff (HFV-12), Center for Veterinary Medicine, 
Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855. 
Send one self-addressed adhesive label to assist that office in 
processing your requests. See the SUPPLEMENTARY INFORMATION section for 
electronic access to the draft guidance document.

FOR FURTHER INFORMATION CONTACT: Kristin Davis, Office of Policy, 
Office of the Commissioner, 10903 New Hampshire Ave., Bldg. 32, Rm. 
4252, Silver Spring, MD 20993-0002, 301-796-0418; or Catherine Gray, 
Center for Drug Evaluation and Research, Food and Drug Administration, 
10903 New Hampshire Ave., Bldg. 51, Rm. 3203, Silver Spring, MD 20993-
0002, 301-796-1200; or Stephen Ripley, Center for Biologics Evaluation 
and Research, Food and Drug Administration, 10903 New Hampshire Ave., 
Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911; or 
Angela Krueger, Center for Devices and Radiological Health, Food and 
Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1666, 
Silver Spring, MD 20993-0002, 301-796-6380; or Thomas Moskal, Center 
for Veterinary Medicine, Food and Drug Administration, 7519 Standish 
Pl. (HFV-1), Rockville, MD 20855, 240-402-6251.

SUPPLEMENTARY INFORMATION: 

I. Background

    FDA is announcing the availability of a draft guidance for industry 
entitled ``Medical Product Communications That Are Consistent With the 
FDA-Required Labeling--Questions and Answers.'' This draft guidance 
provides information for firms about how FDA evaluates their medical 
product communications, including their promotional materials, that 
present information that is not contained in the FDA-required labeling 
\1\ for the product but that may be consistent with the FDA-required 
labeling for the product.
---------------------------------------------------------------------------

    \1\ As used in the draft guidance, the term FDA-required 
labeling includes the labeling reviewed and approved by FDA as part 
of the medical product marketing application review process. For 
products not subject to premarket approval, but instead subject to 
premarket notification requirements or exempt from premarket review, 
the term also includes the labeling relied on to provide adequate 
directions for use and other information required to appear on the 
label or in labeling.
---------------------------------------------------------------------------

    FDA determines whether a medical product is safe and effective for 
use under the conditions prescribed, recommended, or suggested in the 
proposed labeling submitted to FDA with the product's marketing 
application or submission (and for devices, also during the 
classification process). In making this determination, FDA evaluates 
whether the conditions of use in the proposed labeling are supported by 
the required levels and types of evidence of safety and effectiveness 
and whether the benefits of using the product under those specific 
conditions of use outweigh the risks of the product. After FDA approves 
or clears a medical product, the FDA-required labeling sets forth the 
conditions of use under which the product has been shown to meet the 
relevant standard for marketing, and it provides directions and 
information on how to use the product safely and effectively under 
those conditions.
    Medical product firms have expressed interest in communicating, 
including in promotional materials, data and

[[Page 6577]]

information that are not contained in their products' FDA-required 
labeling but concern the approved/cleared uses of the products. We are 
aware that firms have questions about how FDA determines when such 
communications are consistent with the FDA-required labeling, and how 
they are viewed by FDA.
    The draft guidance describes FDA's thinking on these topics. As 
explained in the draft guidance, a firm's communication of information 
that is not contained in the product's FDA-required labeling, but that 
is determined to be consistent with the FDA-required labeling, is not 
alone considered evidence of a new intended use. However, even if a 
communication is consistent with the FDA-required labeling, the 
representations or suggestions made about the product would misbrand 
the product and could subject firms to enforcement action if the 
representations or suggestions are false or misleading. Accordingly, 
the draft guidance both describes FDA's thinking on the types of 
information that are consistent with the FDA-required labeling and 
provides general recommendations for how this information can be 
conveyed in a truthful and non-misleading way. The draft guidance also 
provides some examples to illustrate these concepts. The 
recommendations provided in the draft guidance to help ensure that 
communications are not false or misleading are specific to 
communications that are consistent with the FDA-required labeling; 
communication of information that is not consistent with the FDA-
required labeling is outside the scope of these recommendations.
    Elsewhere in this issue of the Federal Register, FDA is announcing 
the availability of a draft guidance for industry entitled ``Drug and 
Device Manufacturer Communications With Payors, Formulary Committees, 
and Similar Entities--Questions and Answers.'' This draft guidance 
provides answers to common questions regarding firms' communications of 
health care economic information about their approved prescription 
drugs to payers and similar entities. This draft guidance also 
addresses common questions relating to firms' dissemination of 
information about investigational products to payers before FDA 
approval or clearance of such products.
    In addition, FDA is announcing in this issue of the Federal 
Register that it is reopening the comment period for the notice of 
public hearing that appeared in the Federal Register of September 1, 
2016, concerning manufacturer communications regarding unapproved uses 
of approved or cleared medical products. The comment period will be 
reopened for 90 days, until April 19, 2017. As announced in the notice 
of public hearing, FDA is engaged in a comprehensive review of its 
regulations and policies governing communications by firms about 
unapproved uses of approved or cleared medical products, and the 
comments it receives will inform FDA's policy development in this area.
    FDA will consider the feedback it receives in all three of these 
dockets as the Agency continues to review its policies on firm 
communications about medical products, and interested persons may wish 
to review the documents FDA has issued in all three dockets before 
submitting comments to any of the relevant dockets.
    This draft guidance is being issued consistent with FDA's good 
guidance practices regulation (21 CFR 10.115). The draft guidance, when 
finalized, will represent the current thinking of FDA on certain 
commonly asked questions regarding firms' communications for their 
medical products that may be consistent with the FDA-required labeling. 
It does not establish any rights for any person and is not binding on 
FDA or the public. You can use an alternative approach if it satisfies 
the requirements of the applicable statutes and regulations.

II. Paperwork Reduction Act of 1995

    Under the Paperwork Reduction Act of 1995 (the PRA) (44 U.S.C. 
3501-3520), Federal Agencies must obtain approval from the Office of 
Management and Budget (OMB) for each collection of information they 
conduct or sponsor. ``Collection of information'' is defined in 44 
U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or 
requirements that members of the public submit reports, keep records, 
or provide information to a third party. Section 3506(c)(2)(A) of the 
PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 
60-day notice in the Federal Register concerning each proposed 
collection of information before submitting the collection to OMB for 
approval. To comply with this requirement, FDA is publishing notice of 
the proposed collection of information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.
    Title: Recommended Content of Medical Product Communications That 
Are Consistent With the FDA-Required Labeling.
    Description of Respondents: Respondents to the proposed collection 
of information are manufacturers, packers, and distributors and their 
representatives (firms) of human drugs and devices, including those 
licensed as biological products, and animal drugs.
    Burden Estimate: The draft guidance includes Third-Party Disclosure 
recommendations regarding information that firms should include in 
communications that contain information not found in the FDA-required 
labeling for their medical products but that are consistent with the 
FDA-required labeling (as explained in the draft guidance) if they 
choose to publically disseminate such materials.
    Specifically, FDA recommends that various aspects of study design 
and methodology for studies relied on in such communications be 
disclosed to provide material contextual information (e.g., type of 
study, study objectives, product dosage/use regimens, control(s) used, 
patient population studied), and that material limitations related to 
the study design, methodology, and results also be disclosed in a clear 
and prominent manner to help ensure that the communications are not 
false or misleading.
    Furthermore, FDA recommends that firms accurately characterize and 
contextualize the relevant information about the product, including by 
disclosing unfavorable or inconsistent findings. FDA also recommends 
that firms disclose material contextual information from the FDA-
required labeling in these communications, such as data and information 
from studies in the FDA-required labeling that are relevant to the data 
or information presented in the communication (e.g., if a communication 
provides post-market information about the types and rates of 
occurrence of adverse events that have been observed in practice, the 
communication should also include information from the FDA-required 
labeling about the types and rates of occurrence of adverse reactions

[[Page 6578]]

observed in clinical trials to provide context).
    According to FDA data, approximately 162,000 FDA-regulated 
promotional materials are prepared by approximately 500 firms annually. 
Of these materials, we estimate approximately 5 percent contain unique 
presentations of information consistent with FDA-required labeling, as 
that term is described in the draft guidance, submitted by 
approximately 64 percent (or 324) of the firms. Anticipating the number 
of these FDA-regulated promotional materials will soon increase to 6 
percent, we estimate the 324 firms will prepare and disseminate 
annually 9,720 FDA-regulated promotional materials that contain unique 
presentations of information that is consistent with FDA-required 
labeling, as that term is described in the draft guidance, and that 
therefore are recommended to include the proposed third party 
disclosures. Based on our experience reviewing FDA-regulated 
promotional materials for medical products, we estimate it will take 
respondents approximately 4 hours per unique presentation to prepare 
and incorporate the disclosures recommended in the draft guidance, if 
they choose to disseminate this information.
    We estimate the burden of this collection of information as 
follows:

                                                Table 1--Estimated Annual Third-Party Disclosure Burden 1
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                          Number of
                        Type of information                             Number of      disclosures per    Total annual    Average burden    Total hours
                                                                       respondents       respondent       disclosures     per disclosure
--------------------------------------------------------------------------------------------------------------------------------------------------------
Recommended information to be included when firms choose to                     324                30            9,720                4          38,880
 disseminate communications that are consistent with the FDA-
 required labeling.................................................
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.

III. Electronic Access

    Persons with access to the Internet may obtain the draft guidance 
at either

http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm,
http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm,
http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/default.htm,
http://www.fda.gov/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/default.htm, or
https://www.regulations.gov.

    Dated: January 6, 2017.
Jeremy Sharp,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-01012 Filed 1-18-17; 8:45 am]
 BILLING CODE 4164-01-P



                                                                               Federal Register / Vol. 82, No. 12 / Thursday, January 19, 2017 / Notices                                             6575

                                                  provide this information on the cover                   attention as an element of this effort;                DEPARTMENT OF HEALTH AND
                                                  sheet and not in the body of your                       however, there has been some confusion                 HUMAN SERVICES
                                                  comments and you must identify this                     with respect to FDA’s and EPA’s
                                                  information as ‘‘confidential.’’ Any                    respective jurisdiction over such                      Food and Drug Administration
                                                  information marked as ‘‘confidential’’                  mosquito-related products. We are                      [Docket No. FDA–2016–D–2285]
                                                  will not be disclosed except in                         clarifying circumstances under which
                                                  accordance with 21 CFR 10.20 and other                  such products are regulated by FDA as                  Medical Product Communications That
                                                  applicable disclosure law. For more                     new animal drugs under the FD&C Act                    Are Consistent With the Food and
                                                  information about FDA’s posting of                      and other circumstances under which                    Drug Administration-Required
                                                  comments to public dockets, see 80 FR                   such products are regulated by the EPA                 Labeling—Questions and Answers;
                                                  56469, September 18, 2015, or access                    as pesticides under FIFRA. FDA is                      Draft Guidance for Industry;
                                                  the information at: http://www.fda.gov/                 clarifying that the phrase ‘‘articles (other           Availability
                                                  regulatoryinformation/dockets/
                                                                                                          than food) intended to affect the                      AGENCY:   Food and Drug Administration,
                                                  default.htm.
                                                                                                          structure or any function of the body of               HHS.
                                                     Docket: For access to the docket to
                                                  read background documents or the                        man or other animals’’ in the FD&C                     ACTION:   Notice of availability.
                                                  electronic and written/paper comments                   Act’s drug definition (21 U.S.C.
                                                                                                          321(g)(1)(C)) does not include articles                SUMMARY:   The Food and Drug
                                                  received, go to https://                                                                                       Administration (FDA or Agency) is
                                                  www.regulations.gov and insert the                      intended to function as pesticides by
                                                                                                          preventing, destroying, repelling, or                  announcing the availability of a draft
                                                  docket number, found in brackets in the                                                                        guidance for industry entitled ‘‘Medical
                                                  heading of this document, into the                      mitigating mosquitoes for population
                                                                                                                                                                 Product Communications That Are
                                                  ‘‘Search’’ box and follow the prompts                   control purposes. FDA believes that this               Consistent With the FDA-Required
                                                  and/or go to the Division of Dockets                    interpretation is consistent with                      Labeling—Questions and Answers.’’
                                                  Management, 5630 Fishers Lane, Rm.                      congressional intent and provides a                    This draft guidance provides
                                                  1061, Rockville, MD 20852.                              rational approach for dividing                         information for manufacturers, packers,
                                                     Submit written requests for single                   responsibilities between FDA and EPA                   and distributors and their
                                                  copies of the guidance to the Policy and                in regulating mosquito-related products.               representatives (collectively ‘‘firms’’) of
                                                  Regulations Staff (HFV–6), Center for                                                                          drugs and medical devices for humans,
                                                  Veterinary Medicine, Food and Drug                      II. Significance of Guidance
                                                                                                                                                                 including those that are licensed as
                                                  Administration, 7519 Standish Pl.,                         This level 1 draft guidance is being                biological products, and animal drugs
                                                  Rockville, MD 20855. Send one self-                     issued consistent with FDA’s good                      (collectively ‘‘medical products’’), about
                                                  addressed adhesive label to assist that                 guidance practices regulation (21 CFR                  how FDA evaluates their medical
                                                  office in processing your requests. See                                                                        product communications, including
                                                                                                          10.115). The draft guidance, when
                                                  the SUPPLEMENTARY INFORMATION section                                                                          their promotional materials, that present
                                                                                                          finalized, will represent the current
                                                  for electronic access to the draft                                                                             information that is not contained in the
                                                                                                          thinking of FDA on Regulation of
                                                  guidance document.                                                                                             FDA-required labeling for the product
                                                                                                          Mosquito-Related Products. It does not
                                                  FOR FURTHER INFORMATION CONTACT:                                                                               but that may be consistent with the
                                                                                                          establish any rights for any person and
                                                  Laura R. Epstein, Center for Veterinary                                                                        FDA-required labeling for the product.
                                                                                                          is not binding on FDA or the public.
                                                  Medicine (HFV–1), Food and Drug                                                                                The Agency is issuing this draft
                                                                                                          You can use an alternative approach if
                                                  Administration, 7519 Standish Pl.,                                                                             guidance to explain FDA’s current
                                                  Rockville, MD 20855, 301–796–8558,                      it satisfies the requirements of the
                                                                                                                                                                 thinking on commonly asked questions
                                                  Laura.Epstein@fda.hhs.gov.                              applicable statutes and regulations.
                                                                                                                                                                 regarding such communications in order
                                                  SUPPLEMENTARY INFORMATION:                              III. Electronic Access                                 to provide clarity for firms.
                                                                                                                                                                 DATES: Although you can comment on
                                                  I. Background                                             Persons with access to the Internet                  any guidance at any time (see 21 CFR
                                                     FDA is announcing the availability of                may obtain the draft guidance at either                10.115(g)(5)), to ensure that the Agency
                                                  a draft guidance for industry (GFI) #236                http://www.fda.gov/AnimalVeterinary/                   considers your comment on this draft
                                                  entitled ‘‘Regulation of Mosquito-                      GuidanceComplianceEnforcement/                         guidance before it begins work on the
                                                  Related Products.’’ This draft guidance                 GuidanceforIndustry/default.htm or                     final version of the guidance, submit
                                                  provides information for industry and                   https://www.regulations.gov.                           either electronic or written comments
                                                  other stakeholders regarding regulatory                   Dated: January 11, 2017.                             on the draft guidance by April 19, 2017.
                                                  oversight of mosquito-related products,                                                                        ADDRESSES: You may submit comments
                                                  defined as those articles for use in or on              Leslie Kux,
                                                                                                                                                                 as follows:
                                                  mosquitoes. Given the public health                     Associate Commissioner for Policy.
                                                  implications of mosquito control, FDA                   [FR Doc. 2017–00838 Filed 1–18–17; 8:45 am]            Electronic Submissions
                                                  is providing this draft guidance to                     BILLING CODE 4164–01–P                                   Submit electronic comments in the
                                                  clarify the regulatory oversight of                                                                            following way:
                                                  mosquito-related products, including                                                                             • Federal eRulemaking Portal:
                                                  but not limited to those produced                                                                              https://www.regulations.gov. Follow the
                                                  through biotechnology. This guidance is                                                                        instructions for submitting comments.
                                                  important in light of the public health                                                                        Comments submitted electronically,
mstockstill on DSK3G9T082PROD with NOTICES




                                                  urgency of countering the spread of                                                                            including attachments, to https://
                                                  mosquito-borne disease, such as that                                                                           www.regulations.gov will be posted to
                                                  caused by the Zika virus. Vector control                                                                       the docket unchanged. Because your
                                                  is a critical element of the effort to                                                                         comment will be made public, you are
                                                  combat the spread of mosquito-borne                                                                            solely responsible for ensuring that your
                                                  disease. Novel mosquito control                                                                                comment does not include any
                                                  technologies have gained greater                                                                               confidential information that you or a


                                             VerDate Sep<11>2014   21:20 Jan 18, 2017   Jkt 241001   PO 00000   Frm 00094   Fmt 4703   Sfmt 4703   E:\FR\FM\19JAN1.SGM   19JAN1


                                                  6576                         Federal Register / Vol. 82, No. 12 / Thursday, January 19, 2017 / Notices

                                                  third party may not wish to be posted,                  name and contact information to be                     Biologics Evaluation and Research,
                                                  such as medical information, your or                    made publicly available, you can                       Food and Drug Administration, 10903
                                                  anyone else’s Social Security number, or                provide this information on the cover                  New Hampshire Ave., Bldg. 71, Rm.
                                                  confidential business information, such                 sheet and not in the body of your                      7301, Silver Spring, MD 20993–0002,
                                                  as a manufacturing process. Please note                 comments and you must identify this                    240–402–7911; or Angela Krueger,
                                                  that if you include your name, contact                  information as ‘‘confidential.’’ Any                   Center for Devices and Radiological
                                                  information, or other information that                  information marked as ‘‘confidential’’                 Health, Food and Drug Administration,
                                                  identifies you in the body of your                      will not be disclosed except in                        10903 New Hampshire Ave., Bldg. 66,
                                                  comments, that information will be                      accordance with 21 CFR 10.20 and other                 Rm. 1666, Silver Spring, MD 20993–
                                                  posted on https://www.regulations.gov.                  applicable disclosure law. For more                    0002, 301–796–6380; or Thomas
                                                    • If you want to submit a comment                     information about FDA’s posting of                     Moskal, Center for Veterinary Medicine,
                                                  with confidential information that you                  comments to public dockets, see 80 FR                  Food and Drug Administration, 7519
                                                  do not wish to be made available to the                 56469, September 18, 2015, or access                   Standish Pl. (HFV–1), Rockville, MD
                                                  public, submit the comment as a                         the information at: http://www.fda.gov/                20855, 240–402–6251.
                                                  written/paper submission and in the                     regulatoryinformation/dockets/                         SUPPLEMENTARY INFORMATION:
                                                  manner detailed (see ‘‘Written/Paper                    default.htm.
                                                  Submissions’’ and ‘‘Instructions’’).                       Docket: For access to the docket to                 I. Background
                                                  Written/Paper Submissions                               read background documents or the                          FDA is announcing the availability of
                                                                                                          electronic and written/paper comments                  a draft guidance for industry entitled
                                                     Submit written/paper submissions as                  received, go to https://                               ‘‘Medical Product Communications That
                                                  follows:                                                www.regulations.gov and insert the
                                                     • Mail/Hand delivery/Courier (for                                                                           Are Consistent With the FDA-Required
                                                                                                          docket number, found in brackets in the                Labeling—Questions and Answers.’’
                                                  written/paper submissions): Division of
                                                                                                          heading of this document, into the                     This draft guidance provides
                                                  Dockets Management (HFA–305), Food
                                                                                                          ‘‘Search’’ box and follow the prompts                  information for firms about how FDA
                                                  and Drug Administration, 5630 Fishers
                                                  Lane, Rm. 1061, Rockville, MD 20852.                    and/or go to the Division of Dockets                   evaluates their medical product
                                                     • For written/paper comments                         Management, 5630 Fishers Lane, Rm.                     communications, including their
                                                  submitted to the Division of Dockets                    1061, Rockville, MD 20852.                             promotional materials, that present
                                                  Management, FDA will post your                             Submit written requests for single                  information that is not contained in the
                                                  comment, as well as any attachments,                    copies of the draft guidance to the                    FDA-required labeling 1 for the product
                                                  except for information submitted,                       Division of Drug Information, Center for               but that may be consistent with the
                                                  marked and identified, as confidential,                 Drug Evaluation and Research, Food                     FDA-required labeling for the product.
                                                  if submitted as detailed in                             and Drug Administration, 10001 New                        FDA determines whether a medical
                                                  ‘‘Instructions.’’                                       Hampshire Ave., Hillandale Building,                   product is safe and effective for use
                                                     Instructions: All submissions received               4th Floor, Silver Spring, MD 20993–                    under the conditions prescribed,
                                                  must include the Docket No. FDA–                        0002; Office of Communication,                         recommended, or suggested in the
                                                  2016–D–2285 for ‘‘Medical Product                       Outreach and Development, Center for                   proposed labeling submitted to FDA
                                                  Communications That Are Consistent                      Biologics Evaluation and Research,                     with the product’s marketing
                                                  With the FDA-Required Labeling—                         Food and Drug Administration, 10903                    application or submission (and for
                                                  Questions and Answers; Draft Guidance                   New Hampshire Ave., Bldg. 71, Rm.                      devices, also during the classification
                                                  for Industry; Availability.’’ Received                  3128, Silver Spring, MD 20993–0002;                    process). In making this determination,
                                                  comments will be placed in the docket                   Division of Small Manufacturers,                       FDA evaluates whether the conditions
                                                  and, except for those submitted as                      International and Consumer Assistance,                 of use in the proposed labeling are
                                                  ‘‘Confidential Submissions,’’ publicly                  Office of Communication, Education                     supported by the required levels and
                                                  viewable at https://www.regulations.gov                 and Radiation Programs, Center for                     types of evidence of safety and
                                                  or at the Division of Dockets                           Devices and Radiological Health, Food                  effectiveness and whether the benefits
                                                  Management between 9 a.m. and 4 p.m.,                   and Drug Administration, 10903 New                     of using the product under those
                                                  Monday through Friday.                                  Hampshire Ave., Bldg. 66, Rm. 4613,                    specific conditions of use outweigh the
                                                     • Confidential Submissions—To                        Silver Spring, MD 20993–0002; or to                    risks of the product. After FDA approves
                                                  submit a comment with confidential                      Communications Staff (HFV–12), Center                  or clears a medical product, the FDA-
                                                  information that you do not wish to be                  for Veterinary Medicine, Food and Drug                 required labeling sets forth the
                                                  made publicly available, submit your                    Administration, 7519 Standish Pl.,                     conditions of use under which the
                                                  comments only as a written/paper                        Rockville, MD 20855. Send one self-                    product has been shown to meet the
                                                  submission. You should submit two                       addressed adhesive label to assist that                relevant standard for marketing, and it
                                                  copies total. One copy will include the                 office in processing your requests. See                provides directions and information on
                                                  information you claim to be confidential                the SUPPLEMENTARY INFORMATION section                  how to use the product safely and
                                                  with a heading or cover note that states                for electronic access to the draft                     effectively under those conditions.
                                                  ‘‘THIS DOCUMENT CONTAINS                                guidance document.                                        Medical product firms have expressed
                                                  CONFIDENTIAL INFORMATION.’’ The                         FOR FURTHER INFORMATION CONTACT:                       interest in communicating, including in
                                                  Agency will review this copy, including                 Kristin Davis, Office of Policy, Office of             promotional materials, data and
                                                  the claimed confidential information, in                the Commissioner, 10903 New
                                                                                                                                                                   1 As used in the draft guidance, the term FDA-
                                                  its consideration of comments. The                      Hampshire Ave., Bldg. 32, Rm. 4252,
mstockstill on DSK3G9T082PROD with NOTICES




                                                                                                                                                                 required labeling includes the labeling reviewed
                                                  second copy, which will have the                        Silver Spring, MD 20993–0002, 301–                     and approved by FDA as part of the medical
                                                  claimed confidential information                        796–0418; or Catherine Gray, Center for                product marketing application review process. For
                                                  redacted/blacked out, will be available                 Drug Evaluation and Research, Food                     products not subject to premarket approval, but
                                                  for public viewing and posted on                        and Drug Administration, 10903 New                     instead subject to premarket notification
                                                                                                                                                                 requirements or exempt from premarket review, the
                                                  https://www.regulations.gov. Submit                     Hampshire Ave., Bldg. 51, Rm. 3203,                    term also includes the labeling relied on to provide
                                                  both copies to the Division of Dockets                  Silver Spring, MD 20993–0002, 301–                     adequate directions for use and other information
                                                  Management. If you do not wish your                     796–1200; or Stephen Ripley, Center for                required to appear on the label or in labeling.



                                             VerDate Sep<11>2014   21:20 Jan 18, 2017   Jkt 241001   PO 00000   Frm 00095   Fmt 4703   Sfmt 4703   E:\FR\FM\19JAN1.SGM   19JAN1


                                                                               Federal Register / Vol. 82, No. 12 / Thursday, January 19, 2017 / Notices                                            6577

                                                  information that are not contained in                   communications regarding unapproved                    estimate of the burden of the proposed
                                                  their products’ FDA-required labeling                   uses of approved or cleared medical                    collection of information, including the
                                                  but concern the approved/cleared uses                   products. The comment period will be                   validity of the methodology and
                                                  of the products. We are aware that firms                reopened for 90 days, until April 19,                  assumptions used; (3) ways to enhance
                                                  have questions about how FDA                            2017. As announced in the notice of                    the quality, utility, and clarity of the
                                                  determines when such communications                     public hearing, FDA is engaged in a                    information to be collected; and (4)
                                                  are consistent with the FDA-required                    comprehensive review of its regulations                ways to minimize the burden of the
                                                  labeling, and how they are viewed by                    and policies governing communications                  collection of information on
                                                  FDA.                                                    by firms about unapproved uses of                      respondents, including through the use
                                                     The draft guidance describes FDA’s                   approved or cleared medical products,                  of automated collection techniques,
                                                  thinking on these topics. As explained                  and the comments it receives will                      when appropriate, and other forms of
                                                  in the draft guidance, a firm’s                         inform FDA’s policy development in                     information technology.
                                                  communication of information that is                    this area.                                                Title: Recommended Content of
                                                  not contained in the product’s FDA-                        FDA will consider the feedback it                   Medical Product Communications That
                                                  required labeling, but that is determined               receives in all three of these dockets as              Are Consistent With the FDA-Required
                                                  to be consistent with the FDA-required                  the Agency continues to review its                     Labeling.
                                                  labeling, is not alone considered                       policies on firm communications about                     Description of Respondents:
                                                  evidence of a new intended use.                         medical products, and interested                       Respondents to the proposed collection
                                                  However, even if a communication is                     persons may wish to review the                         of information are manufacturers,
                                                  consistent with the FDA-required                        documents FDA has issued in all three                  packers, and distributors and their
                                                  labeling, the representations or                        dockets before submitting comments to                  representatives (firms) of human drugs
                                                  suggestions made about the product                      any of the relevant dockets.                           and devices, including those licensed as
                                                  would misbrand the product and could                       This draft guidance is being issued                 biological products, and animal drugs.
                                                  subject firms to enforcement action if                  consistent with FDA’s good guidance                       Burden Estimate: The draft guidance
                                                  the representations or suggestions are                  practices regulation (21 CFR 10.115).                  includes Third-Party Disclosure
                                                  false or misleading. Accordingly, the                   The draft guidance, when finalized, will               recommendations regarding information
                                                  draft guidance both describes FDA’s                     represent the current thinking of FDA                  that firms should include in
                                                  thinking on the types of information                    on certain commonly asked questions                    communications that contain
                                                  that are consistent with the FDA-                       regarding firms’ communications for                    information not found in the FDA-
                                                  required labeling and provides general                  their medical products that may be                     required labeling for their medical
                                                  recommendations for how this                            consistent with the FDA-required                       products but that are consistent with the
                                                  information can be conveyed in a                        labeling. It does not establish any rights             FDA-required labeling (as explained in
                                                  truthful and non-misleading way. The                    for any person and is not binding on                   the draft guidance) if they choose to
                                                  draft guidance also provides some                       FDA or the public. You can use an                      publically disseminate such materials.
                                                  examples to illustrate these concepts.                  alternative approach if it satisfies the                  Specifically, FDA recommends that
                                                  The recommendations provided in the                     requirements of the applicable statutes                various aspects of study design and
                                                  draft guidance to help ensure that                      and regulations.                                       methodology for studies relied on in
                                                  communications are not false or                                                                                such communications be disclosed to
                                                                                                          II. Paperwork Reduction Act of 1995                    provide material contextual information
                                                  misleading are specific to
                                                  communications that are consistent                         Under the Paperwork Reduction Act                   (e.g., type of study, study objectives,
                                                  with the FDA-required labeling;                         of 1995 (the PRA) (44 U.S.C. 3501–                     product dosage/use regimens, control(s)
                                                  communication of information that is                    3520), Federal Agencies must obtain                    used, patient population studied), and
                                                  not consistent with the FDA-required                    approval from the Office of Management                 that material limitations related to the
                                                  labeling is outside the scope of these                  and Budget (OMB) for each collection of                study design, methodology, and results
                                                  recommendations.                                        information they conduct or sponsor.                   also be disclosed in a clear and
                                                     Elsewhere in this issue of the Federal               ‘‘Collection of information’’ is defined               prominent manner to help ensure that
                                                  Register, FDA is announcing the                         in 44 U.S.C. 3502(3) and 5 CFR                         the communications are not false or
                                                  availability of a draft guidance for                    1320.3(c) and includes Agency requests                 misleading.
                                                  industry entitled ‘‘Drug and Device                     or requirements that members of the                       Furthermore, FDA recommends that
                                                  Manufacturer Communications With                        public submit reports, keep records, or                firms accurately characterize and
                                                  Payors, Formulary Committees, and                       provide information to a third party.                  contextualize the relevant information
                                                  Similar Entities—Questions and                          Section 3506(c)(2)(A) of the PRA (44                   about the product, including by
                                                  Answers.’’ This draft guidance provides                 U.S.C. 3506(c)(2)(A)) requires Federal                 disclosing unfavorable or inconsistent
                                                  answers to common questions regarding                   Agencies to provide a 60-day notice in                 findings. FDA also recommends that
                                                  firms’ communications of health care                    the Federal Register concerning each                   firms disclose material contextual
                                                  economic information about their                        proposed collection of information                     information from the FDA-required
                                                  approved prescription drugs to payers                   before submitting the collection to OMB                labeling in these communications, such
                                                  and similar entities. This draft guidance               for approval. To comply with this                      as data and information from studies in
                                                  also addresses common questions                         requirement, FDA is publishing notice                  the FDA-required labeling that are
                                                  relating to firms’ dissemination of                     of the proposed collection of                          relevant to the data or information
                                                  information about investigational                       information set forth in this document.                presented in the communication (e.g., if
                                                  products to payers before FDA approval                     With respect to the following                       a communication provides post-market
mstockstill on DSK3G9T082PROD with NOTICES




                                                  or clearance of such products.                          collection of information, FDA invites                 information about the types and rates of
                                                     In addition, FDA is announcing in                    comments on these topics: (1) Whether                  occurrence of adverse events that have
                                                  this issue of the Federal Register that it              the proposed collection of information                 been observed in practice, the
                                                  is reopening the comment period for the                 is necessary for the proper performance                communication should also include
                                                  notice of public hearing that appeared                  of FDA’s functions, including whether                  information from the FDA-required
                                                  in the Federal Register of September 1,                 the information will have practical                    labeling about the types and rates of
                                                  2016, concerning manufacturer                           utility; (2) the accuracy of FDA’s                     occurrence of adverse reactions


                                             VerDate Sep<11>2014   21:20 Jan 18, 2017   Jkt 241001   PO 00000   Frm 00096   Fmt 4703   Sfmt 4703   E:\FR\FM\19JAN1.SGM   19JAN1


                                                  6578                          Federal Register / Vol. 82, No. 12 / Thursday, January 19, 2017 / Notices

                                                  observed in clinical trials to provide                    (or 324) of the firms. Anticipating the               third party disclosures. Based on our
                                                  context).                                                 number of these FDA-regulated                         experience reviewing FDA-regulated
                                                     According to FDA data,                                 promotional materials will soon                       promotional materials for medical
                                                  approximately 162,000 FDA-regulated                       increase to 6 percent, we estimate the                products, we estimate it will take
                                                  promotional materials are prepared by                     324 firms will prepare and disseminate                respondents approximately 4 hours per
                                                  approximately 500 firms annually. Of                      annually 9,720 FDA-regulated                          unique presentation to prepare and
                                                  these materials, we estimate                              promotional materials that contain                    incorporate the disclosures
                                                  approximately 5 percent contain unique                    unique presentations of information that              recommended in the draft guidance, if
                                                  presentations of information consistent                   is consistent with FDA-required                       they choose to disseminate this
                                                  with FDA-required labeling, as that term                  labeling, as that term is described in the            information.
                                                  is described in the draft guidance,                       draft guidance, and that therefore are                  We estimate the burden of this
                                                  submitted by approximately 64 percent                     recommended to include the proposed                   collection of information as follows:

                                                                                         TABLE 1—ESTIMATED ANNUAL THIRD-PARTY DISCLOSURE BURDEN 1
                                                                                                                                                Number of                           Average
                                                                                                                            Number of                            Total annual
                                                                         Type of information                                                 disclosures per                       burden per   Total hours
                                                                                                                           respondents                           disclosures
                                                                                                                                               respondent                          disclosure

                                                  Recommended information to be included when firms
                                                    choose to disseminate communications that are con-
                                                    sistent with the FDA-required labeling .............................       324                   30              9,720             4          38,880
                                                     1 There   are no capital costs or operating and maintenance costs associated with this collection of information.


                                                  III. Electronic Access                                    comment on proposed data collection                   program and grants policies and
                                                    Persons with access to the Internet                     projects, HRSA announces plans to                     requirements under the statute. By
                                                  may obtain the draft guidance at either                   submit an Information Collection                      regulation, recipients are required to
                                                                                                            Request (ICR), described below, to the                submit financial reports annually to
                                                  http://www.fda.gov/Drugs/Guidance                         Office of Management and Budget                       HRSA and the A&E Reports and the CLC
                                                    ComplianceRegulatoryInformation/                        (OMB). Prior to submitting the ICR to                 are HAB’s mechanism to implement that
                                                    Guidances/default.htm,                                  OMB, HRSA seeks comments from the                     requirement. Recipients funded under
                                                  http://www.fda.gov/BiologicsBlood                         public regarding the burden estimate,                 Parts A, B, C, and D of the Ryan White
                                                    Vaccines/GuidanceCompliance                             below, or any other aspect of the ICR.                HIV/AIDS Program (codified under Title
                                                    RegulatoryInformation/Guidances/                        DATES: Comments on this ICR must be                   XXVI of the Public Health Service Act)
                                                    default.htm,                                            received no later than March 20, 2017.                are required to report financial data to
                                                  http://www.fda.gov/MedicalDevices/                                                                              HRSA at the beginning (Allocations
                                                                                                            ADDRESSES: Submit your comments to
                                                    DeviceRegulationandGuidance/                                                                                  Report) and at the end of their grant
                                                    GuidanceDocuments/default.htm,                          paperwork@hrsa.gov or mail the HRSA
                                                                                                            Information Collection Clearance                      cycle (Expenditures Report). Recipients
                                                  http://www.fda.gov/AnimalVeterinary/                                                                            funded under Parts A and B are required
                                                    GuidanceComplianceEnforcement/                          Officer, Room 14N–39, 5600 Fishers
                                                                                                            Lane, Rockville, MD 20857.                            to report information about their service
                                                    GuidanceforIndustry/default.htm, or                                                                           provider contracts in the CLC.
                                                  https://www.regulations.gov.                              FOR FURTHER INFORMATION CONTACT: To
                                                                                                            request more information on the                          The forms will continue to require
                                                    Dated: January 6, 2017.                                 proposed project or to obtain a copy of               recipients to report on how funds are
                                                  Jeremy Sharp,                                             the data collection plans and draft                   allocated and spent on core medical and
                                                  Deputy Commissioner for Policy, Planning,                 instruments, email paperwork@hrsa.gov                 non-core services for persons living
                                                  Legislation, and Analysis.                                or call the HRSA Information Collection               with HIV, and on various program
                                                  [FR Doc. 2017–01012 Filed 1–18–17; 8:45 am]               Clearance Officer at (301) 443–1984.                  components, such as administration,
                                                  BILLING CODE 4164–01–P                                    SUPPLEMENTARY INFORMATION: When                       planning and evaluation, and quality
                                                                                                            submitting comments or requesting                     management. The A & E Reports are
                                                                                                            information, please include the                       identical in the types of information
                                                  DEPARTMENT OF HEALTH AND                                  information request collection title for              they collect. However, the first report
                                                  HUMAN SERVICES                                            reference.                                            tracks the allocation of the award at the
                                                                                                              Information Collection Request Title:               beginning of the grant cycle and the
                                                  Health Resources and Services                                                                                   second report tracks actual expenditures
                                                                                                            Ryan White HIV/AIDS Program:
                                                  Administration                                                                                                  (including carryover dollars) at the end
                                                                                                            Allocation and Expenditure Forms.
                                                                                                              OMB No. 0915–0318—Revision.                         of the grant cycle. The CLC form
                                                  Agency Information Collection                                                                                   identifies a recipient’s contracts with
                                                                                                              Abstract: HRSA’s HIV/AIDS Bureau
                                                  Activities: Proposed Collection: Public                                                                         service providers for the current grant
                                                                                                            (HAB) administers the Ryan White HIV/
                                                  Comment Request; Ryan White HIV/                                                                                year, the contract amount, and the types
                                                                                                            AIDS Program authorized under Title
                                                  AIDS Program: Allocation and                                                                                    of services being provided.
                                                                                                            XXVI of the Public Health Service Act
                                                  Expenditure Forms
                                                                                                            as amended by the Ryan White HIV/                        Need and Proposed Use of the
mstockstill on DSK3G9T082PROD with NOTICES




                                                  AGENCY: Health Resources and Services                     AIDS Treatment Extension Act of 2009.                 Information: Accurate allocation,
                                                  Administration (HRSA), Department of                      The Ryan White HIV/AIDS Program                       expenditure, and service contract
                                                  Health and Human Services.                                Allocation and Expenditure Reports                    records of the recipients receiving Ryan
                                                  ACTION: Notice.                                           (A&E Reports), in conjunction with the                White HIV/AIDS Program funding are
                                                                                                            Consolidated List of Contractors (CLC),               critical to the implementation of the law
                                                  SUMMARY: In compliance with the                           enables HRSA to monitor and track the                 and thus are necessary for HRSA to
                                                  requirement for opportunity for public                    use of grant funds for compliance with                fulfill its responsibilities. The primary


                                             VerDate Sep<11>2014    21:20 Jan 18, 2017   Jkt 241001   PO 00000   Frm 00097   Fmt 4703   Sfmt 4703   E:\FR\FM\19JAN1.SGM   19JAN1



Document Created: 2018-02-01 15:15:14
Document Modified: 2018-02-01 15:15:14
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
ActionNotice of availability.
DatesAlthough you can comment on any guidance at any time (see 21 CFR 10.115(g)(5)), to ensure that the Agency considers your comment on this draft guidance before it begins work on the final version of the guidance, submit either electronic or written comments on the draft guidance by April 19, 2017.
ContactKristin Davis, Office of Policy, Office of the Commissioner, 10903 New Hampshire Ave., Bldg. 32, Rm. 4252, Silver Spring, MD 20993-0002, 301-796-0418; or Catherine Gray, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 3203, Silver Spring, MD 20993- 0002, 301-796-1200; or Stephen Ripley, Center for Biologics Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 71, Rm. 7301, Silver Spring, MD 20993-0002, 240-402-7911; or Angela Krueger, Center for Devices and Radiological Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm. 1666, Silver Spring, MD 20993-0002, 301-796-6380; or Thomas Moskal, Center for Veterinary Medicine, Food and Drug Administration, 7519 Standish Pl. (HFV-1), Rockville, MD 20855, 240-402-6251.
FR Citation82 FR 6575 

2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR